Supercharge your clinical Treg workflow with GMP-compliant cell sorting and manufacturing platforms
Tuesday 11 May 2021 11:00 [EST] 16:00 [BST] 17:00 [CEST]
Alternative time zones
Regulatory T (Treg) cells’ ability to suppress immune responses has made them a promising target for immunotherapy in a number of clinical applications, including the treatment of graft-versus-host disease (GvHD) after haploid stem cell transplantation (HSCT), management of autoimmune diseases like Type 1 diabetes, and many others.
A prerequisite for such applications of Tregs is the ability to effectively isolate and enrich them from donor material, as well as to expand them efficiently to obtain clinically relevant cell numbers in a GMP-compliant manner. Both are processes that many laboratories find challenging.
What will you learn?
- Common challenges in the isolation and expansion of Tregs in clinical settings
- How to achieve GMP-compliant isolation of CD4+CD25+CD127dim/- Tregs utilizing multiparametric cell sorting
- How to obtain clinically relevant numbers of Tregs with an automated, GMP-compliant enrichment and expansion platform
Who may this interest?
- Preclinical investigators working in translational settings of adoptive cell therapies
- Commercial and academic entities running clinical trials with adoptive cell therapies
- Flow cytometry core facility managers
Felix Eppler, PhD
Group Leader, Cell Sorting Product Management
Felix leads the Global Product Management team for the MACSQuant® Tyto® Cell Sorting Platform at Miltenyi Biotec. Prior to this, he worked as a research associate at the LIMES Institute, University of Bonn (Germany), with a strong focus on Molecular Immunology and Cell Biology after having obtained his PhD in Molecular Biomedicine from the University in Bonn in 2017.
Niloufar Monhasery, PhD
Global Product Manager, T-cell Portfolio
Niloufar Monhasery received her PhD in Biology from the University of Düsseldorf (Germany) in 2016. She then continued her studies in cancer research as a postdoctoral fellow at the Princess Margaret Cancer Center in Toronto (Canada), and then at the University Hospital of Cologne (Germany), before joining Miltenyi Biotec as a Global Product Manager for T-cell Immunology.